141 related articles for article (PubMed ID: 7545380)
21. DDAVP in acquired von Willebrand syndrome associated with multiple myeloma.
Takahashi H; Nagayama R; Tanabe Y; Satoh K; Hanano M; Mito M; Shibata A
Am J Hematol; 1986 Aug; 22(4):421-9. PubMed ID: 3088986
[TBL] [Abstract][Full Text] [Related]
22. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
23. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
Giannini S; Mezzasoma AM; Leone M; Gresele P
Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
[TBL] [Abstract][Full Text] [Related]
24. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
25. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
[TBL] [Abstract][Full Text] [Related]
27. Acquired von Willebrand syndrome: features and management.
Mohri H
Am J Hematol; 2006 Aug; 81(8):616-23. PubMed ID: 16823821
[TBL] [Abstract][Full Text] [Related]
28. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
[TBL] [Abstract][Full Text] [Related]
29. Combined haemophilia A and type I von Willebrand's disease: a family study including an evaluation of the effects of DDAVP infusion.
Casonato A; Pontara E; Boscaro M; Dannhauser D; Sartori MT; Girolami A
Haematologia (Budap); 1993; 25(1):57-67. PubMed ID: 8339998
[TBL] [Abstract][Full Text] [Related]
30. Acquired von Willebrand's syndrome due to an inhibitor of IgG specific for von Willebrand's factor in polycythemia rubra vera.
Mohri H; Ohkubo T
Acta Haematol; 1987; 78(4):258-64. PubMed ID: 3122493
[TBL] [Abstract][Full Text] [Related]
31. Response to desmopressin of factors XI, X and V in patients with factor VIII deficiency and von Willebrand disease.
White B; Lawler P; Riddell A; Nitu-Whalley IC; Hermans C; Lee CA; Brown SA
Br J Haematol; 2004 Jul; 126(1):100-4. PubMed ID: 15198739
[TBL] [Abstract][Full Text] [Related]
32. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
[TBL] [Abstract][Full Text] [Related]
33. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis.
Fernández J; Monteagudo J; Bargallo X; Jiménez W; Bosch J; Arroyo V; Navasa M
Hepatology; 2005 Sep; 42(3):627-34. PubMed ID: 16108036
[TBL] [Abstract][Full Text] [Related]
34. Alterations of von Willebrand factor and ristocetin cofactor activity during atrial fibrillation.
Kalyoncu U; Dizdar O; Erkan Duman A; Karadag O; Tufan A; Yucel O; Tayfur O; Sen D; Ulger Z; Kepez A; Kocabas U; Haznedaroglu I
Clin Appl Thromb Hemost; 2009 Feb; 15(1):103-8. PubMed ID: 18160605
[TBL] [Abstract][Full Text] [Related]
35. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction.
Rose SS; Faiz A; Miller CH; Saidi P; Philipp CS
Haemophilia; 2008 May; 14(3):571-8. PubMed ID: 18312366
[TBL] [Abstract][Full Text] [Related]
36. Effect of cryoprecipitate and plasma on plasma von Willebrand factor multimeters and bleeding time in Doberman Pinschers with type-I von Willebrand's disease.
Ching YN; Meyers KM; Brassard JA; Wardrop KJ
Am J Vet Res; 1994 Jan; 55(1):102-10. PubMed ID: 8141483
[TBL] [Abstract][Full Text] [Related]
37. Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery.
Schroth M; Plank C; Meissner U; Eberle KP; Weyand M; Cesnjevar R; Dötsch J; Rascher W
Pediatrics; 2006 Jul; 118(1):e76-84. PubMed ID: 16751617
[TBL] [Abstract][Full Text] [Related]
38. Identification of a His54Gln substitution in von Willebrand factor from a patient with defective binding of factor VIII.
Rick ME; Krizek DM
Am J Hematol; 1996 Apr; 51(4):302-6. PubMed ID: 8602631
[TBL] [Abstract][Full Text] [Related]
39. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
Michiels JJ; Budde U; van der Planken M; van Vliet HH; Schroyens W; Berneman Z
Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107
[TBL] [Abstract][Full Text] [Related]
40. Increased haemorrhagic risk after repeated infusion of highly substituted medium molecular weight hydroxyethyl starch.
Treib J; Haass A; Pindur G; Grauer MT; Jung F; Wenzel E; Schimrigk K
Arzneimittelforschung; 1997 Jan; 47(1):18-22. PubMed ID: 9037438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
